IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting
IN8bio, Inc. (Nasdaq: INAB) announced the launch of its new iPSC-based gamma-delta T cell platform, making it one of the few companies able to create both Vdelta1 and Vdelta2 T cell subtypes. This platform aims to facilitate the scaled manufacturing of 'off-the-shelf' cellular therapies. CEO William Ho highlighted this as a significant advancement, with plans to present data at the ASGCT Annual Meeting from May 16-19, 2022. The company is also set to discuss ongoing clinical trials and its product pipeline during a workshop on May 17, 2022.
- Launch of innovative iPSC-based gamma-delta T cell platform.
- Capability to produce both Vdelta1 and Vdelta2 gamma-delta T cell subtypes.
- Significant progress in developing 'off-the-shelf' cellular therapies.
- Leadership in advancing genetically modified gamma-delta T cells into clinical trials.
- None.
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced the Company’s new induced pluripotent stem cell (iPSC) based gamma-delta T cell platform. We have demonstrated that we are one of the few companies than can differentiate iPSC-derived immune cells and the first to produce both iPSC-derived Vdelta1 (Vd1+) and Vdelta2 (Vd2+) gamma-delta T cell subtypes. This platform represents a new phase in IN8bio’s growth as it advances technology that is designed to enable scaled manufacturing of ‘off-the-shelf’ cellular therapies.
“IN8bio’s iPSC program is an exciting advancement for the Company as we continue to deliver innovations in the field of gamma-delta T cells as well as advance our DeltEx platform and pipeline. We believe our iPSC platform significantly bolsters our capabilities to bring uniform, renewable, ‘off-the-shelf’ therapeutic products to patients,” said William Ho, CEO of IN8bio. “We are leading the field, building on our accomplishments of being the first to advance genetically modified gamma-delta T cells into the clinic and the first to complete multiple repeat dosing of gamma-delta T cells. We look forward to sharing additional details from our exciting iPSC program at ASGCT.”
The Company will present the data at the American Society for Gene & Cell Therapy (ASGCT) 25th Annual Meeting in Washington, DC, May 16 to 19, 2022. In addition, Lawrence Lamb, Ph.D., CSO of IN8bio, will present a podium discussion in Ballroom B on “The Next Generation of gamma-delta T Cell-based Therapies” on May 16, 2022.
The Company will be hosting a Research & Development Workshop on May 17, 2022 from 6-8 p.m. EDT to discuss its new iPSC program and company updates on its strategy and pipeline. The discussion will cover ongoing and upcoming preclinical and clinical milestones, including the upcoming IND filing and Phase Ib/II plans for INB-400 as well as the Company’s two Phase 1 clinical programs in newly diagnosed glioblastoma and leukemia. The webcast can be accessed on the Events & Presentations page of the Company’s website.
| Title: | “The Development of ‘Off-the-Shelf’ Manufacturing Strategies for iPSC-Based Gamma-Delta T Cells” |
| Poster: | Board number M-268 |
| Session: | Cell Therapies I |
| Time/day: | 5:30 to 6:30 p.m. EDT; Monday, May 16, 2022 |
| Presenter: | Yanjie Li, Ph.D. |
| Webcast: | IN8bio Company R&D Workshop |
| Time/Day: | 6:00 to 8:00 p.m. EDT; May 17, 2022 |
| Access: | Events & Presentations page on the IN8bio website |
| Webcast: | IN8bio Company R&D Workshop |
| Time/Day: | 6:00 to 8:00 p.m. EDT; May 17, 2022 |
| Access: | Events & Presentations page on the IN8bio website |
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of IN8bio’s iPSC program; the progress and scope of clinical and preclinical trials for IN8bio’s product candidates; and IN8bio’s ability to achieve planned milestones, including data readouts from its trials. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may not realize the intended benefits of its DeltEx platform; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; expectations for regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in our Annual Report on Form 10-k filed with the Securities and Exchange Commission (SEC) on March 17, 2022, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Contacts
IN8bio, Inc.
Kate Rochlin, Ph.D.
+1 646.600.6438
kmrochlin@in8bio.com
Investors:
Solebury Trout
David Buck
+1 646.378.2927
dbuck@soleburytrout.com
Media:
Burns McClellan, Inc.
Katie Larch / Robert Flamm, Ph.D.
klarch@burnsmc.com / rflamm@burnsmc.com
FAQ
What is the new platform announced by IN8bio (INAB)?
When will IN8bio present its findings at the ASGCT Annual Meeting?
What are the key features of IN8bio's new T cell platform?
What clinical trials is IN8bio (INAB) currently conducting?
What is the significance of the DeltEx platform for IN8bio?
